News 19.05.2020 Zurich-Schlieren, Switzerland, May 19, 2020. Proteomedix, the Swiss cancer diagnostics company announces today the publication of the analytical performance results of Proclarix, Proteomedix lead product for improved prostate cancer diagnostics in the peer-reviewed journal PLOS ONE. The report published today highlights the analytical performance of the two CE-IVD assays that measure...
News 15.05.2020 Zurich-Schlieren, Switzerland, May 15, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced the presentation of preclinical data from three of the company’s programs at the American Academy for Cancer Research (AACR) Virtual Annual Meeting II, June...
News 12.05.2020 Schlieren-Zurich, CH and Chantilly, VA, USA, May 12, 2020. Proteomedix, the Swiss cancer diagnostics company and Dynex Technologies, announce today a strategic partnership enabling Proteomedix to establish automated workflows for their prostate cancer diagnostics test and sell Dynex instruments to the global clinical market. The partnership builds on the longstanding...
News 07.05.2020 Zurich-Schlieren, Switzerland, May 7, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced completion of in vitro potency assessments of its DARPin® candidates targeting live, replicating coronavirus SARS-CoV-2. These candidates show extremely robust antiviral activity,...
News 07.05.2020 Zurich-Schlieren, Switzerland, May 7, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, announced today its interim management statement for the period ending March 31, 2020. “We have responded to the current global pandemic in three ways: ensuring the...